Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P30048
UPID:
PRDX3_HUMAN
Alternative names:
Antioxidant protein 1; HBC189; Peroxiredoxin III; Peroxiredoxin-3; Protein MER5 homolog; Thioredoxin-dependent peroxiredoxin 3
Alternative UPACC:
P30048; B2R7Z0; D3DRC9; E9PH29; P35690; Q0D2H1; Q13776; Q5T5V2; Q96HK4
Background:
Thioredoxin-dependent peroxide reductase, mitochondrial, also known as Peroxiredoxin-3, plays a crucial role in cellular defense against oxidative stress by reducing peroxides to water and alcohols. It is essential for maintaining physical strength and regulating NF-kappa-B activation in the cytosol, highlighting its multifaceted role in cell protection and signaling pathways.
Therapeutic significance:
Linked to Spinocerebellar ataxia, autosomal recessive, 32, and Corneal dystrophy, punctiform and polychromatic pre-Descemet, understanding the role of Thioredoxin-dependent peroxide reductase could open doors to potential therapeutic strategies for these conditions.